Research programme: aurora kinase inhibitors - Chroma TherapeuticsAlternative Names: CCT-129202; Multi-kinase inhibitors - Chroma Therapeutics
Latest Information Update: 15 May 2008
At a glance
- Originator Chroma Therapeutics
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 May 2008 Preclinical development is ongoing
- 09 Mar 2005 Preclinical trials in Cancer in United Kingdom (unspecified route)